Filtered By:
Cancer: Adenocarcinoma

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 766 results found since Jan 2013.

Novel targeted siRNA-loaded hybrid nanoparticles: preparation, characterization and in vitro evaluation
Conclusions: This hybrid nanoparticle delivery system can be used as a platform technology for intracellular delivery of siRNAs to NTSR1-overexpressing tumor cells.
Source: Journal of Nanobiotechnology - September 26, 2015 Category: Nanotechnology Authors: Nneka DimMaryna PerepelyukOlukayode GomesChellappagounder ThangavelYi LiuRobert DenAshakumary LakshmikuttyammaSunday Shoyele Source Type: research

Highly stable polyglutamate derivatives/siRNA polyplex efficiently down-relegate survivin expression and augment the efficacy of cisplatin
In this study, we developed the polyglutamate derivative polymer brush, poly(ethyleneglycol) monomethyl ether-b-polyglutamate-g-spermine (mPEG-b-PG-g-spermine, PPGS), which could efficiently deliver survivin-siRNA under ultra-high dilution and in the presence of salt (NaCl 150mM) and serum (10% FBS), most likely due to its PEG-shelled polymer brush structure. On the contrary, aggregation occurred when PEI/siRNA polyplex dispersed in saline and serum-containing media and PEI polyplex dissociated after making a 256-fold dilution. PPGS/si-survivin polyplex exhibited high cellular uptake efficiency and efficiently down-regulat...
Source: International Journal of Pharmaceutics - April 4, 2016 Category: Drugs & Pharmacology Source Type: research

Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line
Conclusion Our results suggest that the bach1 can be considered as a potent adjuvant in breast cancer therapy.
Source: Biomedicine and Pharmacotherapy - January 13, 2017 Category: Drugs & Pharmacology Source Type: research

Cytoplasmic Delivery of Functional siRNA Using pH-Responsive Nanoscale Hydrogels
Publication date: Available online 8 March 2019Source: International Journal of PharmaceuticsAuthor(s): William B. Liechty, Rebekah L. Scheuerle, Julia E. Vela Ramirez, Nicholas A. PeppasAbstractThe progress of short interfering RNA (siRNA) technologies has unlocked the development of novel alternatives for the treatment of a myriad of diseases, including viral infections, autoimmune disorders, or cancer. Nevertheless, the clinical use of these therapies faces significant challenges, mainly overcoming the charged and large nature of these molecules to effectively enter the cell. In this work, we developed a cationic polyme...
Source: International Journal of Pharmaceutics - March 9, 2019 Category: Drugs & Pharmacology Source Type: research

Extracellular vesicles from human umbilical cord mesenchymal stem cells treated with siRNA against ELFN1-AS1 suppress colon adenocarcinoma proliferation and migration.
This study aimed to explore the regulatory role of ELFN1-AS1 in COAD and construct a gene delivery system based on extracellular vesicles (EVs). We found that ELFN1-AS1 levels were obviously increased in COAD patients and COAD tumor cells. Knockdown of ELFN1-AS1 expression by siRNA inhibited COAD cell proliferation and migration. Moreover, silencing ELFN1-AS1 significantly reduced the activation of extracellular signal-regulated protein kinase (Erk), up-regulated the protein expression of E-cadherin and down-regulated vimentin. In addition, we treated human umbilical cord mesenchymal stem cells (hUCMSCs) with siRNA-ELFN1-A...
Source: American Journal of Translational Research - December 10, 2019 Category: Research Tags: Am J Transl Res Source Type: research

Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stromal Cells as an Efficient Nanocarrier to Deliver siRNA or Drug to Pancreatic Cancer Cells
In conclusion, the use of UC-MSC-derived EVs as a drug delivery system for siRNAs or drugs could be a promising approach for the targeted treatment of PDAC.PMID:37296864 | DOI:10.3390/cancers15112901
Source: Cancer Control - June 10, 2023 Category: Cancer & Oncology Authors: Florian Draguet Nathan Dubois Cyril Bouland Karlien Pieters Dominique Bron Nathalie Meuleman Basile Stamatopoulos Laurence Lagneaux Source Type: research

Targeting A549 lung adenocarcinoma cell growth and invasion with protease‑activated receptor‑1 siRNA.
In conclusion, the present study demonstrated that the progression of A549 cells is able to be inhibited by knockdown of PAR1 expression. Efficient delivery of the specific siRNA targeting PAR1 may be used for further study in clinical cancer therapy. PMID: 24604247 [PubMed - as supplied by publisher]
Source: Molecular Medicine - March 6, 2014 Category: Molecular Biology Authors: Wu Z, Zeng Y, Zhong M, Wang B Tags: Mol Med Rep Source Type: research

A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA
In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit...
Source: Theranostics - June 13, 2015 Category: Molecular Biology Authors: Feng Yin, Chengbin Yang, Qianqian Wang, Shuwen Zeng, Rui Hu, Guimiao Lin, Jinglin Tian, Siyi Hu, Rong Feng Lan, Ho Sup Yoon, Fei Lu, Kuan Wang, Ken-Tye Yong Tags: Research Paper Source Type: research

Abstract 768: A kinome-wide siRNA screen identifies modifiers of sensitivity to the EGFR T790M-targeted tyrosine kinase inhibitor (TKI), AZD9291, in EGFR mutant lung adenocarcinoma
In conclusion, through a kinome wide siRNA screen, we identified that gene products in the MAP kinase signaling pathway modify sensitivity to AZD9291. Such sensitivity may be associated with ERK re-phosphorylation within 96h of drug treatment. Collectively, these data suggest rational drug combinations that could be used to forestall resistance to AZD9291. Additional hits from the screen are currently under investigation.This study is supported by AstraZeneca Oncology Innovative Medicines, National Institutes of Health (NIH) NCI grants R01-CA121210, P01-CA129243, U54-CA143798, and the Uehara Memorial Foundation.Citation Fo...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Ichihara, E., Bauer, J. A., Lu, P., Ye, F., Cross, D., Pao, W., Lovly, C. M. Tags: Experimental and Molecular Therapeutics Source Type: research

Chemotherapy priming of the Pancreatic Tumor Microenvironment Promotes Delivery and Anti-Metastasis Efficacy of Intravenous Low-Molecular-Weight Heparin-Coated Lipid-siRNA Complex
Conclusion: These results suggested our sequential delivery of PTX-Lip and LH-Lip/siBCL-2 might provide a practical approach for PDAC or other ECM-rich tumors.
Source: Theranostics - June 13, 2019 Category: Molecular Biology Authors: Qianwen Yu, Yue Qiu, Xiaoxiao Chen, Xuhui Wang, Ling Mei, Haiyao Wu, Kai Liu, Yayuan Liu, Man Li, Zhirong Zhang, Qin He Tags: Research Paper Source Type: research

In vivo delivery of siRNA targeting vasohibin‐2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer
This article is protected by copyright. All rights reserved.
Source: Cancer Science - September 1, 2013 Category: Cancer & Oncology Authors: Takahiro Koyanagi, Yasuhiro Suzuki, Yasushi Saga, Shizuo Machida, Yuji Takei, Hiroyuki Fujiwara, Mitsuaki Suzuki, Yasufumi Sato Tags: Original Article Source Type: research

Abstract A30: A genome-wide siRNA screen in mammalian cells for regulators of S6 phosphorylation
To identify the cellular components that participate in the regulation of mTOR complex 1 (mTORC1), the amino acid-dependent, rapamycin-inhibitable complex, we carried out a genome-wide RNAi depletion screen. We employed a rabbit monoclonal antibody specific for RPS6 [Ser235P/Ser236P] and high content microscopy to quantify rpS6 phosphorylation in the pancreatic ductal adenocarcinoma cancer cell line (PDAC) MiaPaCa-2. Applying a stringent selection, we retrieved over 600 genes wherein at least two RNAi gave significant reduction in S6 phosphorylation. This cohort is significantly enriched in genes whose depletion affects th...
Source: Molecular Cancer Therapeutics - July 6, 2015 Category: Cancer & Oncology Authors: Papageorgiou, A., Tamayo, P., Mesirov, J., Avruch, J., Rapley, J. Tags: PI3K-mTOR Activation in Human Cancer: Poster Presentations - Proffered Abstracts Source Type: research

Silencing Aurora-A with siRNA inhibits cell proliferation in human lung adenocarcinoma cells.
In this study, we investigated the expression of AURKA in lung adenocarcinoma tissues, the role of small interference RNA targeting AURKA on growth, cell cycle, and apoptosis of lung adenocarcinoma cell lines in vitro. The AURKA is highly expressed in lung adenocarcinoma tissues and human lung adenocarcinoma cell lines. Lentivirus-mediated short hairpin RNA (shRNA) was used to knock down AURKA expression in human lung adenocarcinoma cell lines H1299 and A549. The results indicated that depletion of AURKA could inhibit cell growth, cause cell cycle arrest and apoptosis. The potential mechanisms of AURKA inhibition induced ...
Source: International Journal of Oncology - August 31, 2016 Category: Cancer & Oncology Authors: Zhong N, Shi S, Wang H, Wu G, Wang Y, Ma Q, Wang H, Liu Y, Wang J Tags: Int J Oncol Source Type: research

Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells
ConclusionsOur results highlight KRT17 as a possible biomarker in gastric cancer promoting tumor growth, motility, and invasion, and suggest that KRT17 can be a valuable molecular target for development of anti-gastric cancer-specific therapies.
Source: Gastric Cancer - March 14, 2017 Category: Gastroenterology Source Type: research

siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells.
In conclusion, knockdown of ID1 attenuates the stem cell like-properties of self-renewal in normal GC cells, potentially through the targeting of Nanog and Oct-4, and subsequently decreases cell proliferation and resistance to DDP. The results of the present study suggest that ID1 functions as an oncogene in GC and regulates the stem cell like-properties of gastric cancer cells by targeting Nanog and Oct-4. PMID: 28529558 [PubMed - in process]
Source: Oncology Letters - May 24, 2017 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research